Standout Papers

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women ... 2009 2026 2014 2020 584
  1. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study (2009)
    Bella Kaufman, John R. Mackey et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 9 from Science/Nature 108 standout
Sub-graph 1 of 21

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Glioblastoma Therapy: Past, Present and Future
2024 Standout
12 intermediate papers

Works of Cédric Révil being referenced

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma
2016
Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).
2014
and 4 more

Author Peers

Author Last Decade Papers Cites
Cédric Révil 162 566 305 230 22 793
Daniel C. Koboldt 96 452 202 242 18 784
Anna Maria Cianciulli 211 282 197 151 22 711
Alfredo Marinelli 68 277 141 202 27 678
Qimin He 254 297 184 159 22 742
Mark Gustavson 115 354 152 238 30 801
Cynthia R. Osborne 61 648 268 302 31 894
P. Gómez Pardo 67 525 351 153 26 661
Sharon Wilks 91 673 397 230 48 922
Magdalena Murawska 269 620 614 144 29 928
Ross Carruthers 213 404 165 171 21 746

All Works

Loading papers...

Rankless by CCL
2026